HAIC + donafenib + sintilimab

HAIC + donafenib + sintilimab is a combination therapy regimen being evaluated for the first-line treatment of unresectable intrahepatic cholangiocarcinoma (ICC). The regimen integrates three distinct therapeutic modalities: Hepatic Arterial Infusion Chemotherapy (HAIC) using the GEMOX regimen (gemcitabine and oxaliplatin), which provides high local concentrations of cytotoxic agents directly to the liver; donafenib, an oral multi-kinase inhibitor that targets VEGFR, PDGFR, and the Raf/MEK/ERK pathway to inhibit angiogenesis and tumor proliferation; and sintilimab, a recombinant humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) to enhance anti-tumor immune responses. This synergistic approach, studied in the CHANCE 2203 trial led by Zhongda Hospital, aims to improve local control and systemic efficacy in patients with advanced biliary tract malignancies by leveraging the immunogenic cell death induced by locoregional chemotherapy alongside targeted and immune checkpoint inhibition.

Brand names

TyvytZeponid

Other names

HAIC plus donafenib and sintilimabGEMOX-HAIC + donafenib + sintilimabHepatic Arterial Infusion Chemotherapy + donafenib + sintilimab